• Nile Therapeutics Inc., of San Mateo, Calif., closed its previously announced registered direct offering, raising $1.34 million. The company sold 3.35 million shares of common stock and warrants to purchase an additional 2.5 million shares. Proceeds will help to fund a Phase II trial of cenderitide for heart failure.